Form 4/A for DYN Dyne Therapeutics, Inc.
Accepted 2024-07-03 00:00:00 ET · period of report 2024-06-21 · accession 0000950170-24-081748 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAT | 2024-07-03 | 2024-06-21+ | DYN | HIGH SUSANNA GATTI | COO | M - OptEx | $5.54 | +40.0K | 178.6K | +29% | +$221.6K |
| DMAT | 2024-07-03 | 2024-06-21+ | DYN | HIGH SUSANNA GATTI | COO | S - Sale+OE | $35.09 | -40.0K | 148.8K | -21% | -$1.40M |
| DMAT | 2024-07-03 | 2024-06-21+ | DYN | HIGH SUSANNA GATTI | COO | M - OptEx | $0.00 | -40.0K | 70.7K | -36% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-24 | M | A | 10,213 | $5.54 | 159,005 | D | — | — | (F3) This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein. |
| 2 | Common | Common Stock | 2024-06-24 | S | D | 10,213 | $35.33 | 148,792 | D | — | — | (F3) This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.63, inclusive. (F5) Includes 134,629 unvested RSUs. |
| 3 | Common | Common Stock | 2024-06-21 | M | A | 29,787 | $5.54 | 178,579 | D | — | — | |
| 4 | Common | Common Stock | 2024-06-21 | S | D | 29,787 | $35.01 | 148,792 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. |
| 5 | Derivative | Stock option (right to buy) | 2024-06-24 | M | D | 10,213 | $0.00 | 60,486 | D | $5.54 · — to 2030-07-30 | 10,213 Common Stock | (F3) This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein. (F6) The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. |
| 6 | Derivative | Stock option (right to buy) | 2024-06-21 | M | D | 29,787 | $0.00 | 70,699 | D | $5.54 · — to 2030-07-30 | 29,787 Common Stock | (F6) The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. |